<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CCR8 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CCR8</td></tr>
<tr><td><strong>Full Name</strong></td><td>C-C Chemokine Receptor Type 8</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>3p22.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[2919](https://www.ncbi.nlm.nih.gov/gene/2919)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[604468](https://www.omim.org/entry/604468)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000179934</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P41597](https://www.uniprot.org/uniprot/P41597)</td></tr>
<tr><td><strong>Protein Size</strong></td><td>355 amino acids</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Multiple Sclerosis, Alzheimer's Disease, Atopic Dermatitis, Cancer</td></tr>
</table>
</div>
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CCR8 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CCR8</td></tr>
<tr><td><strong>Full Name</strong></td><td>C-C Chemokine Receptor Type 8</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>3p22.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[2919](https://www.ncbi.nlm.nih.gov/gene/2919)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[604468](https://www.omim.org/entry/604468)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000179934</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P41597](https://www.uniprot.org/uniprot/P41597)</td></tr>
<tr><td><strong>Protein Size</strong></td><td>355 amino acids</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Multiple Sclerosis, Alzheimer's Disease, Atopic Dermatitis, Cancer</td></tr>
</table>
</div>
CCR8 encodes the C-C Chemokine Receptor Type 8, a G protein-coupled receptor primarily expressed on type 2 helper T cells (Th2), regulatory T cells (Tregs), and certain myeloid cell populations. This receptor binds multiple ligands including CCL1 (I-309), CCL16 (MCC-1), CCL17 (TARC), and CCL18 (PARC), making it a central regulator of immune cell trafficking and inflammatory responses. In the nervous system, CCR8-expressing T cells can infiltrate the central nervous system during neuroinflammatory conditions, contributing to disease pathogenesis in multiple sclerosis, Alzheimer's disease, and other neurodegenerative disorders [@chen2018].
CCR8 exhibits restricted expression patterns:
CCR8 is a seven-transmembrane receptor that:
The CCR8 protein contains the canonical GPCR structure:
| Domain | Position | Function |
|--------|----------|----------|
| N-terminus | 1-50 aa | Ligand binding, glycosylation |
| Transmembrane helices | 51-280 aa | 7 TM domains, signal transduction |
| Extracellular loops | Variable | Ligand recognition |
| Intracellular loops | Variable | G protein coupling |
| C-terminus | 281-355 aa | Internalization, desensitization |
CCR8 binds multiple chemokines with different affinities:
CCR8 plays a critical role in T cell migration:
Tregs expressing CCR8 have distinct functional properties [@barsema2021]:
In type 2 immune responses, CCR8:
CCR8 is implicated in MS through multiple mechanisms [@mitsdoerffer2005]:
T cell infiltration:
In AD, CCR8 contributes to neuroinflammation [@rostamian2021]:
| Approach | Mechanism | Status |
|----------|-----------|--------|
| Anti-CCR8 antibodies | Deplete CCR8+ T cells | Preclinical/Phase 1 |
| CCR8 antagonists | Block ligand binding | Discovery |
| CCL1 neutralizing antibodies | Prevent receptor activation | Research |
| Treg modulation | Enhance suppressive function | Clinical trials |
Several CCR8-targeted approaches are in development:
Monoclonal antibodies:
Under normal conditions, CCR8 expression in the brain is minimal. However, during neuroinflammation:
The CCR8-CCL1 axis influences BBB function:
CCR8 couples primarily to Gi/o family G proteins, initiating a cascade of intracellular signaling events that regulate immune cell function [@iwasaki2019]. Upon ligand binding, the receptor undergoes conformational changes that promote GDP release from the Gα subunit and GTP binding, leading to dissociation of the Gα-GTP and Gβγ subunits. The Gi/o α subunit inhibits adenylate cyclase activity, reducing intracellular cAMP levels, while the Gβγ subunit activates phosphatidylinositol 3-kinase (PI3K) and phospholipase C (PLC) pathways.
The downstream signaling consequences include activation of the MAPK cascade (ERK1/2, p38, JNK), which regulates gene expression programs controlling cell survival, proliferation, and cytokine production. The PI3K-AKT pathway promotes cell survival and metabolic reprogramming, while PLCγ generates inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to calcium mobilization and protein kinase C (PKC) activation. These signaling events collectively shape the functional responses of CCR8-expressing cells.
Like other GPCRs, CCR8 undergoes desensitization through β-arrestin-mediated processes. Following phosphorylation by G protein-coupled receptor kinases (GRKs), β-arrestin binding sterically blocks further G protein coupling and targets the receptor for internalization via clathrin-coated pits. The internalized receptor can be recycled back to the plasma membrane or targeted for lysosomal degradation, providing a mechanism to modulate receptor availability and signal duration.
β-arrestins also serve as signaling scaffolds, linking CCR8 to downstream effectors independent of G protein signaling. This bias toward β-arrestin-dependent pathways offers opportunities for therapeutic targeting, as selective biased agonists could potentially promote beneficial signaling while minimizing adverse effects.
CCR8 activation triggers distinct transcriptional programs in different immune cell subsets. In Th2 cells, CCR8 signaling promotes expression of GATA3, IL-4, IL-5, and IL-13, reinforcing the Th2 polarization state. In Tregs, CCR8 activation enhances FoxP3 expression and immunosuppressive function, characterized by increased IL-10, TGF-β, and CTLA-4 expression. The transcriptional outcomes depend on the cellular context and integration with other signaling inputs, including T cell receptor engagement and cytokine milieu.
In Alzheimer's disease, CCR8 contributes to neuroinflammation through multiple mechanisms [@yang2021]. The amyloid-β (Aβ) peptide, the primary component of amyloid plaques in AD brain, induces expression of CCL1 and other CCR8 ligands in astrocytes and microglia. This creates a chemotactic gradient that recruits CCR8-expressing T cells to the brain parenchyma.
The recruited T cells release pro-inflammatory cytokines that potentiate microglial activation, creating a feed-forward loop of neuroinflammation. Elevated levels of CCL1 have been detected in cerebrospinal fluid from AD patients, and CCR8+ T cell infiltration has been observed in post-mortem AD brain tissue. The specific roles of CCR8+ Tregs in this context remain complex—while Tregs typically suppress inflammation, their dysfunction in AD may lead to inappropriate immune responses that exacerbate neuronal damage.
Therapeutic strategies targeting the CCL1-CCR8 axis in AD include neutralizing antibodies against CCL1, small molecule CCR8 antagonists, and approaches to enhance Treg function. Preclinical studies in AD mouse models have shown promise, with CCR8 blockade reducing T cell infiltration and ameliorating cognitive deficits.
In Parkinson's disease, CCR8-mediated immune responses contribute to the progressive loss of dopaminergic neurons in the substantia nigra pars compacta [@petrovic2022]. Neuroinflammation is a hallmark of PD, with activated microglia and infiltrating T cells surrounding remaining neurons and contributing to their demise.
CCR8+ T cells have been detected in the cerebrospinal fluid and substantia nigra of PD patients. The chemotactic recruitment of these cells is driven by upregulated CCL1 expression in the PD brain, particularly in regions of active neurodegeneration. Once in the CNS, CCR8+ cells release cytokines that activate microglia and promote oxidative stress, contributing to neuronal death.
Interestingly, CCR8+ Tregs may play dual roles in PD—they can suppress harmful inflammation but may also become dysfunctional and lose their immunosuppressive capacity as disease progresses. This "Treg exhaustion" phenomenon is observed in multiple neurodegenerative conditions and represents a potential therapeutic target.
In ALS, CCR8 expression is altered on both peripheral immune cells and CNS-infiltrating lymphocytes. The progressive loss of motor neurons in ALS is accompanied by robust neuroinflammation, with T cells contributing to both protective and pathogenic processes.
CCR8+ T cells have been identified in ALS spinal cord, where they may influence microglial activation states and motor neuron survival. Studies in mouse models of ALS suggest that CCR8 blockade could modify disease progression by altering the balance between pro-inflammatory and regulatory T cell populations.
Multiple sclerosis represents perhaps the clearest case for CCR8 involvement in neuroinflammatory disease [@nishikazi2019]. In MS, CCR8+ T cells accumulate in active demyelinating lesions, where they contribute to myelin destruction and impede remyelination. The CCL1-CCR8 axis promotes recruitment of Th2 cells and Tregs to the CNS, with the net effect being immunopathology.
Therapeutic targeting of CCR8 in MS has shown promise in preclinical models. Anti-CCR8 antibodies reduce T cell infiltration into the CNS, decrease demyelination, and improve functional outcomes in experimental autoimmune encephalomyelitis (EAE), the standard mouse model of MS. Several pharmaceutical companies have advanced CCR8-targeting agents into clinical development for autoimmune diseases.
CCR8 is highly expressed on type 2 helper T cells, which produce IL-4, IL-5, IL-13, and other cytokines that drive eosinophil recruitment, IgE production, and tissue remodeling. In the context of neuroinflammation, Th2 cells may contribute to repair processes through their production of growth factors, though they can also perpetuate pathology in chronic conditions.
A subset of Tregs expressing CCR8 has been identified in both mouse and human tissues [@sawatzky2020]. These CCR8+ Tregs exhibit enhanced suppressive function compared to CCR8- Tregs and are enriched in non-lymphoid tissues. In the CNS, CCR8+ Tregs may play crucial roles in maintaining immune homeostasis and preventing excessive inflammation following injury or infection.
CCR8 is a marker for tissue-resident memory T cells (Trm) in certain tissues, particularly skin and mucosal surfaces. These cells provide rapid recall responses to pathogens but can also contribute to autoimmune pathology when self-antigens are targeted.
Beyond Th2 and Tregs, CCR8 can be expressed on effector T cells with various polarization states. The functional consequences of CCR8 signaling depend on the broader transcriptional program of the cell, which is determined by differentiation history and tissue microenvironment.
Several anti-CCR8 antibodies are in development for oncology and autoimmune disease applications [@tommi2021]. In cancer, the goal is to deplete tumor-infiltrating CCR8+ Tregs, thereby releasing anti-tumor immune responses. In autoimmune conditions, blocking CCR8 prevents pathogenic T cell recruitment to target tissues.
Early clinical trials have demonstrated target engagement and preliminary efficacy signals, though optimal dosing and combination strategies continue to be explored. Key considerations include the need for peripheral versus tissue-resident targeting and potential effects on beneficial T cell populations.
Small molecule antagonists offer advantages including oral bioavailability and potential for tissue penetration. Several pharmaceutical companies have identified CCR8 antagonists through high-throughput screening and structure-based design. These compounds block CCL1 binding and prevent receptor activation, providing an alternative to antibody-based approaches.
CCR8 expression may serve as a biomarker for disease activity and treatment response in neuroinflammatory conditions. CCR8+ T cell counts in cerebrospinal fluid correlate with disease severity in MS, and changes following treatment may predict outcomes. Similarly, in AD and PD, CCR8+ T cell measurements could provide insights into neuroinflammatory status.
The most effective therapeutic strategies may involve combination approaches targeting multiple aspects of neuroinflammation. Potential combinations include CCR8 blockade with:
Several model systems are used to study CCR8 function:
Surface CCR8 detection uses specific antibodies for flow cytometry. Common markers for characterizing CCR8+ populations include:
Cell culture models allow mechanistic study of CCR8 signaling:
Several important questions remain about CCR8 biology:
New directions include:
The following diagram shows the key molecular relationships involving CCR8 Gene discovered through SciDEX knowledge graph analysis: